Literature DB >> 14568809

Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2.

Oscar L Lopez1, William J Jagust, Corinne Dulberg, James T Becker, Steven T DeKosky, Annette Fitzpatrick, John Breitner, Constantine Lyketsos, Beverly Jones, Claudia Kawas, Michelle Carlson, Lewis H Kuller.   

Abstract

OBJECTIVE: To examine the risk factors for mild cognitive impairment (MCI) in a longitudinal population study-the Cardiovascular Health Study Cognition Study.
DESIGN: We examined the factors that in the period 1991 through 1994 predicted the development of MCI in all participants of the Cardiovascular Health Study Cognition Study. Further examination was conducted in the Pittsburgh, Pa, cohort (n = 927), where participants with MCI were classified as having either the MCI amnestic-type or the MCI multiple cognitive deficits-type.
SETTING: Multicenter population study. PATIENTS: This study includes all participants of the Cardiovascular Health Study Cognition Study (n = 3608) who had a magnetic resonance imaging (MRI) scan of the brain between 1991 and 1994, and detailed neuropsychological, neurological, and medical evaluations to identify the presence of MCI or dementia in the period 1998 to 1999. The mean time between the closest clinical examination to the MRI and the diagnostic evaluation for cognitive disorders was 5.8 years for the Cardiovascular Health Study Cognition Study cohort and 6.0 years for the Pittsburgh cohort. MAIN OUTCOME MEASURES: Risk factors for MCI at the time of the MRI were identified using logistic regression, controlling for age, race, educational level, baseline Modified Mini-Mental State Examination and Digit Symbol Test scores, measurements of depression, MRI findings (atrophy, ventricular volume, white matter lesions, and infarcts), the presence of the apolipoprotein E (APOE) epsilon4 allele, hypertension, diabetes mellitus, and heart disease.
RESULTS: Mild cognitive impairment (n = 577) was associated with race (African American), low educational level, low Modified Mini-Mental State Examination and Digit Symbol Test scores, cortical atrophy, MRI-identified infarcts, and measurements of depression. The MCI amnestic-type was associated with MRI-identified infarcts, the presence of the APOE epsilon4 allele, and low Modified Mini-Mental State Examination scores. The MCI multiple cognitive deficits-type was associated with low Modified Mini-Mental State Examination and Digit Symbol Test scores.
CONCLUSIONS: The development of MCI is associated with measurements of cognition and depression, racial and constitutional factors, and cerebrovascular disease. Early cognitive deficits seem to be a common denominator for the 2 forms of MCI; the presence of cerebrovascular disease and the APOE epsilon4 allele is associated with the amnestic type of MCI.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14568809     DOI: 10.1001/archneur.60.10.1394

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  120 in total

Review 1.  Patterns of compensation and vulnerability in normal subjects at risk of Alzheimer's disease.

Authors:  Oscar L Lopez; James T Becker; Lewis H Kuller
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

2.  Caregiving and cognitive function in older women: evidence for the healthy caregiver hypothesis.

Authors:  Rosanna M Bertrand; Jane S Saczynski; Catherine Mezzacappa; Mallorie Hulse; Kristine Ensrud; Lisa Fredman
Journal:  J Aging Health       Date:  2011-09-20

3.  A national neuroimaging database: a call to action.

Authors:  David M Yousem; R Nick Bryan; Norman J Beauchamp; Alice M Arnold
Journal:  AJNR Am J Neuroradiol       Date:  2004 Jun-Jul       Impact factor: 3.825

Review 4.  Mild cognitive impairment: pathology and mechanisms.

Authors:  Elliott J Mufson; Lester Binder; Scott E Counts; Steven T DeKosky; Leyla de Toledo-Morrell; Stephen D Ginsberg; Milos D Ikonomovic; Sylvia E Perez; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-11-19       Impact factor: 17.088

5.  An exploration of subgroups of mild cognitive impairment based on cognitive, neuropsychiatric and functional features: analysis of data from the National Alzheimer's Coordinating Center.

Authors:  John J Hanfelt; Joanne Wuu; Ann B Sollinger; Melanie C Greenaway; James J Lah; Allan I Levey; Felicia C Goldstein
Journal:  Am J Geriatr Psychiatry       Date:  2011-11       Impact factor: 4.105

6.  Slower gait, slower information processing and smaller prefrontal area in older adults.

Authors:  Caterina Rosano; Stephanie A Studenski; Howard J Aizenstein; Robert M Boudreau; William T Longstreth; Anne B Newman
Journal:  Age Ageing       Date:  2011-09-28       Impact factor: 10.668

7.  Neuromarkers of the common angiotensinogen polymorphism in healthy older adults: A comprehensive assessment of white matter integrity and cognition.

Authors:  Lauren E Salminen; Peter R Schofield; Kerrie D Pierce; Yi Zhao; Xi Luo; Youdan Wang; David H Laidlaw; Ryan P Cabeen; Thomas E Conturo; David F Tate; Erbil Akbudak; Elizabeth M Lane; Jodi M Heaps; Jacob D Bolzenius; Laurie M Baker; Lee M Cagle; Robert H Paul
Journal:  Behav Brain Res       Date:  2015-08-28       Impact factor: 3.332

8.  The Hachinski ischemic scale and cognition: the influence of ethnicity.

Authors:  Leigh A Johnson; Blair Cushing; Geoffrey Rohlfing; Melissa Edwards; Hedieh Davenloo; Darrin D'Agostino; James R Hall; Sid E O'Bryant
Journal:  Age Ageing       Date:  2013-12-08       Impact factor: 10.668

Review 9.  Clinically asymptomatic vascular brain injury: a potent cause of cognitive impairment among older individuals.

Authors:  Charles DeCarli
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

10.  Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders.

Authors:  Daniel E Weiner; Keith Bartolomei; Tammy Scott; Lori Lyn Price; John L Griffith; Irwin Rosenberg; Andrew S Levey; Marshal F Folstein; Mark J Sarnak
Journal:  Am J Kidney Dis       Date:  2008-12-12       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.